MYCN and neuroblastoma: The third sample, the zPDX from the neuroblastoma culture with MYCN amplification and PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) mutation, responded only moderately to the ALK inhibitor ceritinib out of five tested drugs.